Skip to search formSkip to main contentSkip to account menu

VX680

Known as: VX-680, MK-0457, MK0457 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

Aurora kinase inhibitor MK-0457Piperazines

Narrower (2)

TozasertibVE 465

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Activity of the Aurora Kinase Inhibitor VX-680 against Bcr/Abl-Positive Acute Lymphoblastic Leukemias
The emergence of resistance to tyrosine kinase inhibitors due to point mutations in Bcr/Abl is a challenging problem for… 
2010
2010
Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.
2010
2010
3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: selective Aurora A kinase inhibitors.
2008
2008
Inhibitors of ABL and the ABL-T315I mutation.
Chronic myelogenous leukemia (CML) is a hematological stem cell disorder caused by increased and unregulated growth of myeloid… 
2008
2008
Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells.
2006
2006
A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients.
3009 Background: The AKs are essential for mitotic progression, spindle formation, centrosome maturation, chromosomal segregation… 
Review
2006
Review
2006
New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Imatinib mesylate, Abl tyrosine kinase inhibitor, has improved the treatment of Bcr-Abl-positive leukemia such as chronic myeloid… 
2006
2006
MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL.
Background. MK-0457 (VX-680) is a small-molecule inhibitor of aurora kinases A, B, and C, FLT3, BCR-ABL, and JAK2. MK-0457… 
Review
2004
Review
2004
Dawn of Aurora kinase inhibitors as anticancer drugs
With the current standard chemotherapy regimens only ∼ 25% of acute myelogenous leukaemia (AML) patients survive > 5 years… 
2004
2004
Aurora kinases dawn as cancer drug targets
A new anticancer compound interferes with aurora kinases, regulators of mitosis. We can now hope for the biology of these kinases… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)